Literature DB >> 2428411

Differential modulation of dopamine D2 receptors by chronic haloperidol, nitrendipine, and pimozide.

L H Tecott, L L Kwong, S Uhr, S J Peroutka.   

Abstract

Chronic administration of the neuroleptic haloperidol, the calcium channel antagonist nitrendipine, and the calcium channel antagonist neuroleptic pimozide produce differential effects on rat striatal 3H-spiperone binding. Following 7 days of 10 mg/kg i.p. administration, haloperidol significantly increases (p less than 0.01) dopamine D2 receptor binding to 123% +/- 6% of control values, whereas pimozide treatment significantly reduces (p less than 0.001) striatal 3H-spiperone binding to 46% +/- 6% of control values. Chronic administration of the calcium channel antagonist nitrendipine does not alter 3H-spiperone binding relative to control values. Saturation analysis reveals an increase in Bmax following chronic haloperidol and a decrease in Bmax following chronic pimozide treatment. No alterations in muscarinic cholinergic sites, dopamine uptake sites, or calcium channel antagonist sites result following chronic drug administration. These results are the first demonstration of a decrease in dopamine D2 binding sites after chronic neuroleptic treatment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428411     DOI: 10.1016/0006-3223(86)90219-2

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  6 in total

1.  Pimozide augmentation in a patient with drug-resistant psychosis previously treated with olanzapine.

Authors:  J Takhar
Journal:  J Psychiatry Neurosci       Date:  1999-05       Impact factor: 6.186

2.  Behavioural tests of the dopamine depletion hypothesis of neuroleptic-induced response decrement.

Authors:  P Willner; G Phillips; R Muscat; P Hood
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy.

Authors:  Joseph I Friedman; Jean-Pierre Lindenmayer; Frances Alcantara; Stephanie Bowler; Mohan Parak; Leonard White; Adel Iskander; Michael Parrella; David N Adler; Nicholas D Tsopelas; Wei-Yann Tsai; Vladan Novakovic; Vladan Novakovick; Philip D Harvey; Kenneth L Davis; Saurabh Kaushik
Journal:  Neuropsychopharmacology       Date:  2011-02-23       Impact factor: 7.853

4.  Effects of chronic haloperidol on stress-induced oral behaviour in rats.

Authors:  J N Nobrega; L M Dixon; L R Troncone; H T Barros
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

5.  Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.

Authors:  L Schafranek; E Nievergall; J A Powell; D K Hiwase; T Leclercq; T P Hughes; D L White
Journal:  Leukemia       Date:  2014-05-12       Impact factor: 11.528

6.  The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer.

Authors:  El-Habib Dakir; Adam Pickard; Kirtiman Srivastava; Cian M McCrudden; Stephane R Gross; Stephen Lloyd; Shu-Dong Zhang; Andriana Margariti; Richard Morgan; Philip S Rudland; Mohamed El-Tanani
Journal:  Oncotarget       Date:  2018-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.